Latest Pharma Insights
Ulta Beauty Posts Double-Digit Growth on ‘Record’ Holiday, Omnichannel Strength
Ulta Beauty Inc. reported its holiday season ‘served as a culmination of our efforts to advance the business throughout 2025,’ with sales growing double digits. The firm executed ‘outstanding’ in-store and digital execution, bold marketing campaigns and a ‘compelling’ holiday assortment.
HBW Insight - March 14, 2026
Ulta Beauty Inc. reported its holiday season ‘served as a culmination of our efforts to advance the business throughout 2025,’ with sales growing double digits. The firm executed ‘outstanding’ in-store and digital execution, bold marketing campaigns and a ‘compelling’ holiday assortment.
HBW Insight - March 14, 2026
Finance Watch: As IPO Market Quiets Again, Xenon, Dianthus Price Big Follow-Ons
Public Company Edition: There have been no biopharma IPOs in the US since Generate Medicines at the end of February, but a new SPAC could provide a go-public option. In follow-on offerings, Xenon raised $747.5m and Dianthus brought in $719m based on recent milestones.
Scrip - March 13, 2026
Public Company Edition: There have been no biopharma IPOs in the US since Generate Medicines at the end of February, but a new SPAC could provide a go-public option. In follow-on offerings, Xenon raised $747.5m and Dianthus brought in $719m based on recent milestones.
Scrip - March 13, 2026
Many Blockbuster Brands Set To Fade In 2026
Merck, Johnson & Johnson, AstraZeneca and Roche are among the big pharma manufacturers that will face substantial exclusivity losses in the US this year.
Scrip - March 13, 2026
Merck, Johnson & Johnson, AstraZeneca and Roche are among the big pharma manufacturers that will face substantial exclusivity losses in the US this year.
Scrip - March 13, 2026
Another Late-Stage LAG-3 Trial Bites The Dust As Immutep Ends Efti NSCLC Study
The biotech stopped a Phase III trial combining Merck’s Keytruda with eftilagimod alfa in first-line non-small cell lung cancer due to futility.
Scrip - March 13, 2026
The biotech stopped a Phase III trial combining Merck’s Keytruda with eftilagimod alfa in first-line non-small cell lung cancer due to futility.
Scrip - March 13, 2026
Deal Watch: Enodia Turns To Kezar To Advance Sec61 Programs
Plus deals involving Rapport/Tenacia, Servier/Kyron.bio, Pfizer/Aska, TransCode/Unleashed Immune Oncolytics, Gedeon Richter/Celmatix and recent AI/ML-focused alliances.
Scrip - March 13, 2026
Plus deals involving Rapport/Tenacia, Servier/Kyron.bio, Pfizer/Aska, TransCode/Unleashed Immune Oncolytics, Gedeon Richter/Celmatix and recent AI/ML-focused alliances.
Scrip - March 13, 2026
Regenxbio Reinforces Case for Its Duchenne Gene Therapy Amid Accelerated Approval Uncertainty
After recent upheaval at the US FDA, the company’s CEO is unsure that an agreed fast-track pathway will still be in place for its Duchenne gene therapy, RGX-202.
Scrip - March 13, 2026
After recent upheaval at the US FDA, the company’s CEO is unsure that an agreed fast-track pathway will still be in place for its Duchenne gene therapy, RGX-202.
Scrip - March 13, 2026
CEO Chaplin Leaves Bavarian Nordic In Decent Shape
As the Danish vaccine maker plots further M&A activity.
Scrip - March 13, 2026
As the Danish vaccine maker plots further M&A activity.
Scrip - March 13, 2026
FDA Weight Loss Device Guidance Calls For Patient Focus
A new final guidance document from the US FDA lays out premarket considerations for devices intended to help treat obesity, including clinical trial design, labeling, and safety concerns. The guidance also calls for sponsors to consider patient perceptions in evaluating device effectiveness.
Medtech Insight - March 13, 2026
A new final guidance document from the US FDA lays out premarket considerations for devices intended to help treat obesity, including clinical trial design, labeling, and safety concerns. The guidance also calls for sponsors to consider patient perceptions in evaluating device effectiveness.
Medtech Insight - March 13, 2026
Stryker Cyberattack Disrupts Order Processing And Manufacturing Across Global Operations
Stryker's global operations were thrown into disarray on Mar. 11 after an Iran-linked hacking group brought down its Microsoft environment overnight. Order processing, manufacturing and shipping are disrupted. A full recovery timeline remains unknown.
Medtech Insight - March 13, 2026
Stryker's global operations were thrown into disarray on Mar. 11 after an Iran-linked hacking group brought down its Microsoft environment overnight. Order processing, manufacturing and shipping are disrupted. A full recovery timeline remains unknown.
Medtech Insight - March 13, 2026
VBP, Reimbursement Cuts And Uncertain Outlook: How Medtech’s Biggest Players Are Reading China
China is still medtech's most consequential market conversation. Across Medtronic, Roche, Abbott and peers, the headwinds vary, the timelines differ and the strategic consequences are only beginning to surface.
Medtech Insight - March 13, 2026
China is still medtech's most consequential market conversation. Across Medtronic, Roche, Abbott and peers, the headwinds vary, the timelines differ and the strategic consequences are only beginning to surface.
Medtech Insight - March 13, 2026
FDA And Industry To Move Forward On Commitment Letter After Agreeing On Several Proposals
During the latest round of MDUFA negotiations, the FDA and medtech industry agreed to include language in the next commitment letter that would provide direction for the use of carryover funds from user fees. The parties also found agreement on several other topics.
Medtech Insight - March 13, 2026
During the latest round of MDUFA negotiations, the FDA and medtech industry agreed to include language in the next commitment letter that would provide direction for the use of carryover funds from user fees. The parties also found agreement on several other topics.
Medtech Insight - March 13, 2026
Ulta Beauty Posts Double-Digit Growth on ‘Record’ Holiday, Omnichannel Strength
Ulta Beauty Inc. reported its holiday season ‘served as a culmination of our efforts to advance the business throughout 2025,’ with sales growing double digits. The firm executed ‘outstanding’ in-store and digital execution, bold marketing campaigns and a ‘compelling’ holiday assortment.
HBW Insight - March 14, 2026
Ulta Beauty Inc. reported its holiday season ‘served as a culmination of our efforts to advance the business throughout 2025,’ with sales growing double digits. The firm executed ‘outstanding’ in-store and digital execution, bold marketing campaigns and a ‘compelling’ holiday assortment.
HBW Insight - March 14, 2026
Sandoz Secures CHF550m Financing Package
Bond issuance and extended revolving credit facility provide financial headroom as the company restructures operations to accelerate biosimilars growth while maintaining generics scale.
Generics Bulletin - March 13, 2026
Bond issuance and extended revolving credit facility provide financial headroom as the company restructures operations to accelerate biosimilars growth while maintaining generics scale.
Generics Bulletin - March 13, 2026
Generic Prozac Tops UK Rises in February As Concessions Mount
A host of unusually high price increases for UK generics in February led the Department of Health and Social Care to issue the highest number of price concessions seen in almost three years.
Generics Bulletin - March 13, 2026
A host of unusually high price increases for UK generics in February led the Department of Health and Social Care to issue the highest number of price concessions seen in almost three years.
Generics Bulletin - March 13, 2026
Podcast: Onchilles Pharma’s Neutrophil-Derived Path To Pan-Cancer Therapy
San Diego-based Onchilles Pharma's neutrophil-derived ELANE pathway agent N17350 targets a universal cancer vulnerability, combining direct tumor killing with immune activation. It is now entering first-in-human trials across solid tumors.
In Vivo - March 12, 2026
San Diego-based Onchilles Pharma's neutrophil-derived ELANE pathway agent N17350 targets a universal cancer vulnerability, combining direct tumor killing with immune activation. It is now entering first-in-human trials across solid tumors.
In Vivo - March 12, 2026